New Therapy for Colon Cancer Using Antibody-Directed Enzyme-Drug Approach
Author Information
Author(s): Deckert P M, Renner C, Cohen L S, Jungbluth A, Ritter G, Bertino J R, Old L J, Welt S
Primary Institution: Universitätsklinikum Benjamin Franklin, Freie Universität Berlin
Hypothesis
Can a recombinant protein construct improve the effectiveness of antibody-directed enzyme-prodrug therapy (ADEPT) for colon cancer?
Conclusion
The A33scFv–CD fusion protein significantly increased the cytotoxicity of the prodrug 5-fluorocytosine in A33-positive colon cancer cells.
Supporting Evidence
- The A33 antibody targets a specific antigen found on 95% of colon cancers.
- The fusion protein showed a dose-dependent cytotoxic effect on A33-positive cells.
- Incubation with the A33scFv–CD construct increased prodrug toxicity by about 300-fold.
Takeaway
Scientists created a special protein that helps a cancer drug work better by targeting it directly to colon cancer cells.
Methodology
The study involved creating and testing a fusion protein in vitro for its ability to target and kill colon cancer cells using a prodrug.
Limitations
The study was conducted in vitro, and results may not directly translate to in vivo effectiveness.
Statistical Information
P-Value
p=0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website